Xenetic Biosciences Company

Xenetic Biosciences PLC (formerly Lipoxen PLC) Xenetic is a leading UK-based clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Their product pipeline includes: PolyXen™ is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (rFVIII). XBIO-101 (sodium cridanimod): XBIO-101 is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue.
Technology: Drug Discovery
Industry: Preventive Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2014
Employees Number: 11-50
Funding Status: N/A

Visit Website
info@xeneticbio.com
@XeneticBio
Register and Claim Ownership